Portal de Periódicos da CAPES

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

2014; Elsevier BV; Volume: 123; Issue: 12 Linguagem: Inglês

10.1182/blood-2013-11-538835

1528-0020

Paul G. Richardson, David S. Siegel, Ravi Vij, Craig C. Hofmeister, Rachid Baz, Sundar Jagannath, Christine Chen, Sagar Lonial, Andrzej Jakubowiak, Nizar J. Bahlis, Kevin Song, Andrew Belch, Noopur Raje, Chaim Shustik, Suzanne Lentzsch, Martha Q. Lacy, Joseph Mıkhael, Jeffrey Matous, David H. Vesole, Min Chen, Mohamed H. Zaki, Christian Jacques, Zhinuan Yu, Kenneth C. Anderson,

Cancer Treatment and Pharmacology

Key Points Pomalidomide plus low-dose dexamethasone significantly improved PFS vs pomalidomide alone in relapsed and refractory multiple myeloma. Pomalidomide plus low-dose dexamethasone is an important new treatment option for RRMM patients who have received multiple prior therapies.